1. Pink Sheet
  2. >>Biosimilars & Generics

ANDA Approval Records Will End As US FDA Mops Up Backlog

 
• By Derrick Gingery

CDER Director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.

Businessman looking through a magnifying glass to documents
Once the backlog is cleared, there may be fewer ANDAs for FDA to approve, which may mean records will not continue to be broken each year. • Source: Shutterstock

The US Food and Drug Administration's record generic drug approval numbers in recent years was partially a function of a large application backlog, according to Center for Drug Evaluation and Research Director Janet Woodcock.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Biosimilars & Generics